Navigation Links
Supplemental New Drug Application Submitted to FDA for NUCYNTA® ER (Tapentadol) Extended-Release Tablets for Diabetic Peripheral Neuropathic Pain
Date:10/31/2011

ccurs more frequently in elderly or debilitated patients and in those suffering from conditions accompanied by hypoxia, hypercapnia, or upper airway obstruction, in whom even moderate therapeutic doses may significantly decrease pulmonary ventilation.
  • Use NUCYNTA® ER with caution in patients with conditions accompanied by hypoxia, hypercapnia, or decreased respiratory reserve, such as: asthma, chronic obstructive pulmonary disease or cor pulmonale, severe obesity, sleep apnea syndrome, myxedema, kyphoscoliosis, central nervous system (CNS) depression, or coma. In such patients, even usual therapeutic doses of NUCYNTA® ER may increase airway resistance and decrease respiratory drive to the point of apnea. Alternative non–mu-opioid agonist analgesics should be considered, and NUCYNTA® ER should be employed only under careful medical supervision at the lowest effective dose in such patients. If respiratory depression occurs, it should be treated as any mu-opioid agonist-induced respiratory depression.
  • Patients receiving other opioid agonist analgesics, general anesthetics, phenothiazines, other tranquilizers, sedatives, hypnotics, centrally acting muscle relaxants, or other CNS depressants (including alcohol) concomitantly with NUCYNTA® ER may exhibit additive CNS depression. Interactive effects resulting in respiratory depression, hypotension, profound sedation, coma, or death may result if these drugs are taken in combination with NUCYNTA® ER. When such combined therapy is contemplated, a dose reduction of one or both agents should be considered.
  • Opioid analgesics can raise cerebrospinal fluid pressure as a result of respiratory depression with carbon dioxide retention. Therefore, NUCYNTA® ER should not be used in patients who may be susceptible to the effects of raised cerebrospinal fluid pressure, such as those with evidence of head injury and increased intracranial pressure. Opioid analgesics may obscure the clinical
    '/>"/>

  • SOURCE Janssen Pharmaceuticals Research & Development
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

    Related medicine technology :

    1. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
    2. ORENCIA(R) (abatacept) Supplemental Biologics License Application for Juvenile Idiopathic Arthritis Accepted by FDA for Filing and Review
    3. FDA Accepts Wyeths Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia
    4. Supplemental New Drug Application for PREZISTA(TM) Submitted to U.S. Food and Drug Administration
    5. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
    6. CTI to Meet With the FDA to Discuss Filing of a Supplemental Biologics License Application for Zevalin(R)
    7. Anesiva Announces FDA Approval of Supplemental New Drug Application to Expand Zingo(TM) Indication
    8. FDA Grants Priority Review of a Supplemental Biologics License Application for Cinryze(TM) C1 Inhibitor (Human) as Treatment for Acute Attacks of Hereditary Angioedema (HAE)
    9. Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder
    10. Sanofi Pasteur Submits Supplemental Application for A(H1N1) Pandemic Vaccine to U.S. FDA
    11. Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associated with Jet Lag Disorder
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/6/2015)... July 6, 2015 Hologic, Inc. (NASDAQ: ... release its financial results for the third quarter of ... market closes.  In conjunction with the release, management will ... Eastern Time. Interested participants may listen to ... United States ) or 719-325-4804 (for international callers) ...
    (Date:7/6/2015)... DUBLIN , June 29, 2015 ... the addition of the "Pharmaceutical Grade Sodium Chloride ... Forecasts to 2019" report to their offering. ... to witness a CAGR of 6.9% between 2014 and ... anticipated to reach 690 KT by 2019. ...
    (Date:7/6/2015)... BOULDER, Colo. , July 6, 2015 /PRNewswire/ ... inhibitor, encorafenib, was showcased this past weekend at ... during an oral presentation.  At the meeting, data ... preliminary data from a 100-patient randomized Phase 2 ... encorafenib and cetuximab, an EGFR inhibitor, with or ...
    Breaking Medicine Technology:Hologic to Announce Financial Results for the Third Quarter of Fiscal 2015 on Wednesday, July 29, 2015 2Global Pharmaceutical Grade Sodium Chloride Market Report 2015 2Global Pharmaceutical Grade Sodium Chloride Market Report 2015 3Encorafenib-Based Regimens Show Promising Clinical Activity In BRAF-Mutant Colorectal Cancer Patients 2Encorafenib-Based Regimens Show Promising Clinical Activity In BRAF-Mutant Colorectal Cancer Patients 3Encorafenib-Based Regimens Show Promising Clinical Activity In BRAF-Mutant Colorectal Cancer Patients 4
    ... 2011 Grifols, a global healthcare company and ... the structure of its new North American Commercial ... U.S. commercial group will be organized by product ... North America.  The Canadian organization, a major presence ...
    ... Inc. (NASDAQ: SLTM ), a global leader in the ... June 30, 2011. Second quarter 2011 revenue was $29.0 million, compared ... the sales of treatment tips and consumables grew 10% as compared ... total revenue.   GAAP net loss for the ...
    Cached Medicine Technology:Grifols Announces New North American Commercial Operations Organization 2Grifols Announces New North American Commercial Operations Organization 3Solta Medical Reports Second Quarter Results 2Solta Medical Reports Second Quarter Results 3Solta Medical Reports Second Quarter Results 4Solta Medical Reports Second Quarter Results 5Solta Medical Reports Second Quarter Results 6Solta Medical Reports Second Quarter Results 7Solta Medical Reports Second Quarter Results 8
    (Date:7/7/2015)... ... July 07, 2015 , ... Clarion ... labels, has been featured in the latest issue of In Compliance Magazine, a ... In Compliance delivers the latest news, standards updates, technical explanations and guidance, ...
    (Date:7/6/2015)... ... 06, 2015 , ... For over twenty years, Doctors on Liens ... Throughout the company’s history the goal has been to be a comprehensive network of ... And while Doctors on Liens has certainly achieved that goal, the addition of ...
    (Date:7/6/2015)... ... July 06, 2015 , ... “ TapGlance ” was ... the latest and coolest applications on the market for iOS, Android, and Windows. Joe ... with viewers how this interior design app helps users visualize what rooms will look ...
    (Date:7/6/2015)... ... July 06, 2015 , ... Acara Partners, a leading business ... of its complimentary educational webinar series for the summer of 2015. ... for their clients through targeted marketing, sales, digital communications, branding and business development ...
    (Date:7/6/2015)... ... July 06, 2015 , ... Understanding the new ICD-10 ... is leading the transition. ADVOCATE, the only 100% radiology, revenue cycle management company ... for ICD-10. The ten tips are timely and relevant guidelines to help radiology ...
    Breaking Medicine News(10 mins):Health News:Standards Considerations for Laser Safety Labels from Clarion Safety Systems Featured in In Compliance Magazine 2Health News:Standards Considerations for Laser Safety Labels from Clarion Safety Systems Featured in In Compliance Magazine 3Health News:Standards Considerations for Laser Safety Labels from Clarion Safety Systems Featured in In Compliance Magazine 4Health News:Doctors on Liens Adds Transportation to Its Ever-Expanding Network 2Health News:Doctors on Liens Adds Transportation to Its Ever-Expanding Network 3Health News:Create a Space with TapGlance, a Revolutionary Interior Design Application 2Health News:Acara Partners Announces Complimentary Educational Webinar Series for Cosmetic Medical Practices and MedSpas 2Health News:Acara Partners Announces Complimentary Educational Webinar Series for Cosmetic Medical Practices and MedSpas 3Health News:ADVOCATE Takes the Lead to Ensure ICD-10 Success: “Top 10 Tips for ICD-10” 2
    ... ... Medicine, SACRAMENTO, Calif., March 10 ... U.S. employment opportunities for,veterinarians are expected to increase faster than the overall ... 700 new veterinarians per year to keep up with retirement and the,ever-growing ...
    ... 100 Latino leaders in California participated, MANHATTAN BEACH, ... largest ethnic group by 2011 and the majority of,California,s ... in,California is uninsured, the highest rate among all ethnic ... thing politicians are discussing,with regard to the Latino community ...
    ... model for human malignant mesothelioma (MM) that will provide ... new directions for design of therapeutic strategies. The research, ... Cancer Cell, may eventually lead to a substantially improved ... MM is an aggressive cancer originating from the mesothelial ...
    ... Creates Innovative, Inviting, Child-Friendly Online Information Source for ... Healthcare Professionals ... http://www.searchhope.org , LOS ... companies, has created an innovative, inviting,child-friendly web-based portal that allows sick ...
    ... who do not comply with treatment instructions for osteoporosis ... likely to suffer further fractures, which seriously affects their ... to provide support to these patients and address their ... guidelines drawn up, according to lead researcher Professor Cyrus ...
    ... shuttle Endeavor blasts off on March 11, some ... from Arizona State Universitys Biodesign Institute. , The ... part of the STS-123 space shuttle Endeavor mission. ... Nickerson, PhD, project leader and scientist in the ...
    Cached Medicine News:Health News:Shortage Creates Increased Job Prospects in Veterinary Medicine 2Health News:Shortage Creates Increased Job Prospects in Veterinary Medicine 3Health News:New Survey Shows Solutions to Improve Latinos' Access to Health Care in California 2Health News:Mouse model for mesothelioma reproduces human disease 2Health News:Siegel+Gale Designs New 'HOPE Portal' for Childrens Hospital Los Angeles 2Health News:Siegel+Gale Designs New 'HOPE Portal' for Childrens Hospital Los Angeles 3Health News:Make or break time for osteoporosis treatment 2Health News:Microscopic 'astronauts' to go back in orbit 2Health News:Microscopic 'astronauts' to go back in orbit 3
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    Medicine Products: